Blog
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy
Maravai LifeSciences Holdings, Inc. (MRVI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings
Kosmos Energy (KOS) Upgraded to Buy: What Does It Mean for the Stock?
Investors might want to bet on Kosmos Energy (KOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates --
Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even
UMB (UMBF) Upgraded to Strong Buy: Here's What You Should Know
UMB Financial (UMBF) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates
Jabil (JBL) Is Up 0.24% in One Week: What You Should Know
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
What's Wrong With Transportation Sector? Buy These ETFs Instead
The Dow Jones Transportation Average has cooled Wall Street’s recent record run, slipping below its February breakout level and wiping out April’s surge toward 25,000, as quoted on Yahoo Finance.
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx Pharmaceutical RARE reported first-quarter 2026 loss of $1.84 per share, wider than the Zacks Consensus Estimate of a loss of $1.55. The company had incurred a loss of $1.57 per share in
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
Exelixis, Inc. EXEL reported mixed results for the first quarter of 2026.
Adjusted earnings per share (EPS) of 87 cents comfortably beat the Zacks Consensus Estimate of 75 cents. The company posted
Evergy to Post Q1 Earnings: What's in Store for the Stock This Season?
Evergy, Inc. EVRG is scheduled to release first-quarter 2026 results on May 7, before market open. The company delivered a negative earnings surprise of 26.32% in the last reported quarter.Let us
BWA Q1 Earnings Beat Estimates on Cost Controls, Charging Exit
BorgWarner Inc. BWA delivered adjusted earnings of $1.24 per share in the first quarter of 2026, beating the Zacks Consensus Estimate of $1.16 by 6.83%. Revenues of $3.53 billion topped the Zacks
COR Stock Falls on Q2 Earnings & Revenue Miss, FY26 EPS View Raised
Cencora, Inc. COR reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of $4.75, which missed the Zacks Consensus Estimate of $4.80 by 1%. The bottom line improved 7.5% year over
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas Medicine EDIT incurred a loss of 26 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 43 cents
Kraft Heinz Q1 Earnings Beat Estimates Despite Organic Sales Dip
The Kraft Heinz Company KHC posted first-quarter 2026 results, wherein both top and bottom lines beat the Zacks Consensus Estimate. While net sales increased, earnings decreased from the year-ago
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
TransMedics Group TMDX delivered earnings per share (EPS) of 30 cents in the first quarter of 2026, down 59.5% year over year. The figure missed the Zacks Consensus Estimate by 51.6%.
TMDX’s Q1
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
Novo Nordisk A/S NVO reported adjusted first-quarter 2026 earnings of $1.04 per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 87 cents. The company had reported
ADNT Q2 Earnings Beat on Revenue Growth and Solid Execution
Adient plc ADNT delivered an earnings beat in the second quarter of fiscal 2026, even as profitability cooled year over year. Adjusted earnings were 52 cents per share, down 24.6% from 69 cents a
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
Repligen Corporation RGEN reported first-quarter 2026 adjusted earnings per share of 48 cents, which beat the Zacks Consensus Estimate of 38 cents. In the year-ago quarter, the company reported
Global Payments Q1 Earnings Beat Estimates on Worldpay Momentum
Global Payments, Inc. GPN reported first-quarter 2026 adjusted earnings per share (EPS) of $2.96, which beat the Zacks Consensus Estimate of $2.82. The bottom line rose 10% year over year.
Adjusted
TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down
Tempus AI, Inc. TEM reported a first-quarter 2026 adjusted loss of 13 cents per share compared with the year-ago quarter’s loss of 24 cents. The figure was narrower than the loss per share estimate
Cipher Digital Q1 Loss Wider Than Expected, Revenues Decline Y/Y
Cipher Digital Inc. CIFR reported a first-quarter 2026 loss of 28 cents per share, which came wider than the Zacks Consensus Estimate of a loss of 27 cents. The company reported a loss of 11 cents
Logitech's Q4 Earnings Surpass Estimates, Revenues Rise Y/Y
Logitech International S.A. LOGI reported fourth-quarter fiscal 2026 non-GAAP earnings of $1.13 per share, which beat the Zacks Consensus Estimate by 2.7%. The bottom line increased 22% on a
Are Markets Sleepwalking Into Recession? ETFs for Portfolio Resilience
The S&P 500 has extended its upward momentum, gaining 1.27% over the past five days and 11.46% over the past month, as easing oil prices boosted overall risk sentiment. The recent pullback in energy
THC Beats Q1 Earnings Estimates on Strong Ambulatory Growth, Ups '26 EPS View
Tenet Healthcare Corporation THC reported first-quarter 2026 adjusted earnings per share (EPS) of $4.82, which surpassed the Zacks Consensus Estimate by 14.5%. The bottom line increased 10.6% year



